Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Metastatic Medullary Thyroid Cancer
NCT02657551Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jan 2016
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in Medullary Thyroid Cancer (MTC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Progression-free Survival Rate at 10 months and Objective Response Rate at 23.9 months. Started Jan 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT02657551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02657551.